+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
MALE
ID07226986

Study of AMO959 With Lutetium 177Lu Vipivotide Tetraxetan and Androgen Receptor Pathway Inhibitors in Adult Males With PSMA-positive Metastatic Castration Resistant Prostate Cancer

Led by Novartis Pharmaceuticals · Updated on 2026-10-15

123

Participants Needed

25

Research Sites

61 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and preliminary effectiveness of AMO959 combined with lutetium 177Lu vipivotide tetraxetan AAA617 and androgen receptor pathway inhibitors ARPIs in adult men with PSMA-positive metastatic castration resistant prostate cancer mCRPC. This study includes participants who have failed one prior ARPI treatment, with or without previous taxane chemotherapy exposure. The study has two phases Phase Ib focuses on safety and dosing, and Phase II evaluates preliminary efficacy. The study consists of two phases. Phase Ib includes three dose level groups assessing AMO959 alone first, then combined with AAA617 and ARPI abiraterone or enzalutamide. Dose escalation meetings determine the recommended dose for expansion. Phase II randomizes participants into three arms to receive AMO959 with AAA617 and ARPI, AAA617 with ARPI, or other combinations, with treatments given in cycles up to six times every six weeks. Participants will receive study drugs in scheduled cycles and undergo regular assessments including monitoring for dose-limiting toxicities, adverse events, dose adjustments, drug exposure, and biochemical responses such as PSA levels. Safety and treatment effects are tracked up to approximately 24 to 45 months. The study involves multiple visits for treatment and follow-up evaluations, measuring outcomes like progression-free survival, response rates, and quality of life.

CONDITIONS

Brief Title

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here